



Sino-American Pharmaceutical Professionals Association

Career Development Workshop

9:00 am – 5:30 pm
Saturday, January 23rd, 2010
Robert Wood Johnson Medical School
675 Hoes Lane West - Piscataway, NJ 08822
Main Lecture Hall Auditorium

Registration fees

SAPA members: \$25

Non-members: \$40

Students: \$15

Lunch is provided

On-line pre-registration at <http://sapaweb.org> is strongly encouraged (onsite \$10 extra each)

Registration begins: 8:00 am

Opening Remarks 9:00 am

Handan He, Ph.D., Ning Yan, Ph.D., Cai Li, Ph.D.

Introduction of SAPA 9:05 am

Jisong Cui, PhD, SAPA President

AM Sessions:

1. 9:15 am – 9:50 am

“Career Opportunities in China: Observations and Reflections”

Dr. Steve Q. Yang

Vice President, Head of R&D, Asia

Pfizer PharmaTherapeutics R&D

E-mail: steve.q.yang@pfizer.com

2. 9:50 am – 10:25 am

"Career Management and Leadership in a Changing Environment"

Dr. Bei B. Zhang

Senior Director and Franchise Basic Site Lead – Diabetes

Merck Research Laboratories

E-mail: bei_zhang@merck.com

BREAK 10:25 am – 10:40 am

3. 10:40 am – 11:15 am

"Skating to Where the Money Will Be"

Mr. Danny Chaing

Head, Statistical Programming – CNS/Internal Medicine/Virology

Biostatistics & Programming Center of Excellence (CoE)

Global Drug Development (GDO)

Johnson & Johnson

E-mail: DChaing@its.jnj.com

4. 11:15 am – noon

Mr. Zhongying Mao

Counselor of Science & Technology

Consulate General of the People's Republic of China

LUNCH BREAK noon - 1 pm (lunch will be provided)

PM Sessions:

1. The development and current status of Beijing Pharmaceutical and biotech industry
--Lei Ting, Director-General, Beijing Pharma and Biotech Center
2. The policies for overseas talents coming back to Beijing- Beijing Overseas Talents Center
--Sun Wei, Chief of Administrative Management Department, Beijing Overseas Talents Center
3. The development and preferential policies in the science parks
--Yin Hao, Clerk Officer, Zhongguancun National Innovation Model Park
--Wang Xiaoyu, Project Manager, BDA Industry Promotion Bureau, Beijing Economic-Technological Development Area
4. Company presentations and their needs for talents:
-- Luo Xielong, Deputy General Manager, Beijing Pharmaceutical Group Co., Ltd (BPGC)
-- Lu Jiaxuan, Deputy Manager of Human Resources Department, Beijing Pharmaceutical Group Co., Ltd
-- Zhang Yu, Vice President, Beijing Double-Crane Pharmaceutical Co., Ltd
-- Han Hongxia, Manager of Human Resources Department, Beijing Double-Crane Pharmaceutical Co., Ltd
-- Zhang Wei, Manager of Human Resources Department, Beijing Second Pharmaceutical Co., Ltd
-- Wang Ke, General Manager, Beijing Collab Pharma Co., Ltd
-- Li Xiaopeng, CEO, SinoGenoMax Co.,Ltd
-- Xu Mingbo, Chairman of the Board, Beijing SL Pharmaceutical Co.,Ltd
-- Tian Nanhui, Chairman, Beijing Ginke Group Biological Technology Co. Ltd
-- Yang Zhiwei, President, Beijing Co-Lab Bio-Technology Ltd

Panel Discussion 4:45 pm – 5:30 pm

Bios and Abstracts

“Career Opportunities in China: Observations and Reflections”

Dr. Steve Q. Yang

Dr. Steve Yang is Vice President, Head of Asia R&D, Pfizer PharmaTherapeutics R&D. He is a member of Pfizer PharmaTherapeutics R&D's leadership team. Based in Shanghai, China, Dr. Yang focuses on developing and implementing Pfizer's Asia R&D strategy. Prior to his current role, Dr. Yang was Head of Research, Asia for Pfizer. His responsibilities included exploring R&D capabilities of Asia countries, establishing and managing partnerships with biotech companies, academic research institutions, and R&D service providers. Earlier, Steve was an Executive Director and the global head of Pfizer Global R&D's Strategic Management Group. His main responsibilities included providing strategic advice and consulting service to the senior R&D leaders and managing a global team of internal consultants. He received a Pfizer Global R&D Achievement Award in 2003.

Prior to Pfizer, Steve held positions of varying responsibilities at IntraBiotics Pharmaceuticals, an emerging biotech company in California. Steve also worked for Strategic Decisions Group (SDG), a boutique management consulting firm specialized in strategy consulting for Fortune 100 companies.

Dr. Yang is the co-founder of the BayHelix Group, a non-profit professional organization of Chinese life science business leaders.

Steve received his PhD in Pharmaceutical Chemistry from University of California, San Francisco. He started his undergraduate study in Fudan University, Shanghai, China and completed his BS Summa Cum Laude in Biology from Michigan Technological University.

“Career Management and Leadership in a Changing Environment”

Dr. Bei B. Zhang

Dr. Zhang is Senior Director and Franchise Basic Site Lead – Diabetes at Merck Research Laboratories. She is leading the group that focuses on discovery of medicines for the treatment of diabetes and related metabolic disorders. Dr. Zhang is responsible for directing research ranging from target validation to delivery of candidates for development. Dr. Zhang has played an important role in the discovery and the launch of JANUVIA®, a novel oral therapy for the treatment of type 2 diabetes.

Dr. Zhang received her BS degree at Fudan University, PhD degree in Biochemistry and Molecular Biology at Indiana University School of Medicine and completed a postdoctoral fellowship at Stanford University School of Medicine. Since joining Merck 17 years ago, Dr. Zhang has held positions of increasing responsibilities and currently holds a key leadership position in the "Must Win" area at Merck Research Laboratories. She is actively engaged in Diabetes and Obesity franchise strategy setting, research portfolio planning and pipeline management. Dr. Zhang has extensive experience in various areas of drug discovery and development, including 1) new target ID and validation; 2) lead ID and optimization; 3) qualification of preclinical development candidates; and 4) development of candidates through different phases of clinical trials. She has initiated and led numerous projects in the discovery phase and chaired Early Development Teams to guide the preclinical and clinical development of several compounds to achieve proof-of-concept in the clinic. Dr. Zhang has also actively engaged in evaluation and execution of licensing opportunities. Two recent examples include the research collaboration with Metabasis (chair of Joint Research Committee) and licensing and collaboration with Ambrx (scientific champion of the evaluation and the execution of the deal and oversight of the collaboration).

Dr. Zhang has an excellent track record of scientific accomplishment illustrated by lectures at scientific conferences (Keystone, FASEB, Gordon Conferences, ADA, EASD, etc.). She has published over 100 articles in scientific journals (including Science, Nature Medicine, Cell Metabolism, J. Clinical Investigation, Proc. Natl. Acad. Sci., J. Biological Chemistry, Am. J. Physiol., Diabetes, Diabetologia) and authored a number of book chapters. She is well connected to the scientific/academic community with a number of collaborations with key opinion leaders and is widely recognized as an expert in field

“Skating to Where the Money Will Be”

Mr. Danny Chaing

Danny started his pharmaceutical career in Statistics at Hoechst-Roussel Pharmaceutical, Inc in 1977. In the 12 years at American Home Products Corporation (1979-1991), he led data management, statistics, and programming

work in multiple approved NDAs, and Rx-to-OTC conversions. Danny concentrated on Computer-Assisted NDA (CANDA) technologies while working for Rhone-Poulenc Rorer (RPR) from 1991 to 1995. He joined Janssen Research Foundation of J&J in 1995 and had increased responsibilities in data management, and programming in J&J Pharma Companies. His current position is Head, Statistical Programming – CNS/Internal Medicine/Virology, Biostatistics & Programming Center of Excellence (CoE), Global Drug Development (GDO) of J&J. Danny has been active in SAPA, ICSA, and PhRMA (BDMTG).

Danny earned his Bachelor of Science in Statistics from Fu-Jan University, Taiwan. He has Master degree in Statistics from Rutgers University and Master Degree in Computer Science also from Rutgers University.

BPBC Delegates

Governments

No.	Name	Title	Organization	Brief Introduction
1	Lei Ting	Director-General Delegate Leader	Beijing Pharma and Biotech Center	Governmental Agency that is dedicated to promote the biotech and pharmaceutical industry in Beijing by providing consulting services, partnership seeking, conference organizing, technology transfer, international liaison, industry and market strategic research, etc. www.newlife.org.cn
2	Man Qunjie	Division Chief of Outbound Investment Promotion Division	Beijing Investment Promotion Bureau	Governmental agency that promotes investment, providing complete professional services for Chinese and foreign investors, and setting up a bridge between the government and enterprises. http://www.investbeijing.gov.cn/english/
3	Wang Xiaoyu	Project Manager	BDA Industry Promotion Bureau, Beijing Economic-Technological Development Area	BDA is the largest science park of Beijing, standing for 30% of the Beijing gross industry value. Near 200 biotech and pharmaceutical companies locate in BDA, representing over 40% of the Beijing pharmaceutical sales income. www.bda.gov.cn
4	Yin Hao	Clerk Officer	Zhongguancun National Innovation Model Park	The national park in Beijing. Three of its sub-parks are focused on life science and pharmaceutical, which are BDA, ZGC Life Science Park, ZGC Life Science New City(Daxing). www.zgc.gov.cn/english
5	Dong Cui	Vice Director	China Bio-Medicine Industry Park (Daxing) Management Committee	China Bio-Medicine Industry Park (Daxing) is a science park only for pharmaceutical and biotech industry with a complimentary facilitates and resources. http://www.cbp.net.cn/
6	Sun Wei	Chief of Administrative Management Department	Beijing Overseas Talents Center	The municipal center that help overseas talents in Beijing, by providing policies, and originating funding projects for overseas talents. www.8610hr.cn

7	Qi Heng	Manager of International Affairs Dept.	Beijing Pharma and Biotech Center	Governmental Agency that is dedicated to promote the biotech and pharmaceutical industry in Beijing by providing consulting services, partnership seeking, conference organizing, technology transfer, international liaison, industry and market strategic research, etc. www.newlife.org.cn
8	Jiang Nan	Assistant of International Affairs Dept.	Beijing Pharma and Biotech Center	

Enterprises

No.	Name	Title	Organization	Brief Introduction
1	Luo Xielong	Deputy General Manager	Beijing Pharmaceutical Group Co., Ltd (BPGC)	Largest pharmaceutical group in Beijing, TOP 3 in China. It involves in the development, manufacture, and sale of western medicines, bio-medicines, health products, pharmaceutical raw materials, inter-mid, medical equipment, and medicine manufacturing equipment. www.bpgc.com.cn
2	Lu Jiaxuan	Deputy Manager of Human Resources Department	Beijing Pharmaceutical Group Co., Ltd	
3	Zhang Yu	Vice President	Beijing Double-Crane Pharmaceutical Co., Ltd	Subsidiary of BPGC. Jointly established by six legal shareholders on May 15th 1997 and was successfully listed on May 22nd of the same year (Share Code: 600062). As a new & high-tech enterprise and the first approved GMP pharmaceutical company in China, DCPC has set up four great mainstays for business development including the largest i.v solution, injection supply base in China, China's leading production base for synthetic antibiotics, innovation base for natural drugs and nationwide sale and service system. www.dcpc.com/en
4	Han Hongxia	Manager of Human Resources Department	Beijing Double-Crane Pharmaceutical Co., Ltd	
5	Zhang Wei	Manager of Human Resources Department	Beijing Second Pharmaceutical Co., Ltd	Subsidiary of BPGC. BSPC is the prescription drug business division of Beijing Pharmaceutical Group Co., Ltd., a China top five pharmaceutical group, expertizing in pharmaceutical R&D, APIs and generics manufacturing, marketing and distribution in China. With one dosage facility in Beijing (cGMP complianced), one APIs facility in Zhejiang Province (US FDA approved), BSPC is able to meet the intermediates, APIs and dosage production requirements of international clients, with annual production capacity of 1.5 billion tablets, 200 million capsules and 1,800 Mts of APIs.. http://english.saike.com.cn
6	Wang Ke	General Manager	Beijing Collab Pharma Co., LTD	A company that focuses on new drug development, also known as the National Center

7	Zhao Dalong	Deputy General Manger	Beijing Collab Pharma Co., LTD	for Engineering and Technology of New Medicine Development of Institute of Maria Medica, CAMS www.collab.cn/en
8	Chen Xiaoguang	Counselor	Beijing Collab Pharma Co., LTD	
9	Li Xiaopeng	CEO	SinoGenoMax Co.,Ltd	A CRO that provides R&D services in genomics area. One of the undertakers of the Human Genome Project. www.sinogenomax.com
10	Xu Mingbo	Chairman of the Board	Beijing SL Pharmaceutical Co.,Ltd	A high biotechnology-pharmaceutical company, mainly engages in developing and marketing gene engineering drugs. Founded in December 1994, it was listed in Chinese Stock Exchange in 2004. All products have got GMP Authentication issued by Chinese State Food & Drug Administration (SFDA). Management is performed according to the requirements of international GMP standards from workshops, equipments, raw or auxiliary materials, packing materials to production, quality and hygiene. www.slpharm.com.cn
11	Tian Nanhui	Chairman	Beijing Ginke Group Biological Technology Co. Ltd	A company that specialized in the manufacture of high value botanical extracts and derivatives for dietary supplements, pharmaceuticals, cosmetics, food & beverage, tobacco, etc. www.gingkogroup.com.cn
12	Yang Zhiwei	President	Beijing Co-Lab Bio-Technology Ltd	Founded by Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences , it is a comprehensive animal breeding and research facility, dedicated in developing and producing biological models, quality monitoring capabilities and comparative medical technology services for the biomedical researchers. http://www.cnilas.org/html/en/
13	Chen Xingliang	President	Beijing Changxin State-Owned Assets Operation Co., Ltd	A large state-owned asset investment company, invested the Beijing Co-Lab Bio-Technology Ltd. http://www.chxgz.gov.cn/index.html
14	Liu Zhifeng	Professor	University of Yantai, Shangdong	Prof. Liu is an expert of the animal test area and is adviser of many GLP centers in China.

Workshop Organizing Committee:

Jiwen Chen, Kevin Chen, Jisong Cui, Helena Feng, Helen Fu, Handan He, Bao-Guo Huang, Cai Li, Xing Li, Kun Liu, Jianji Wang, Mingde Xia, Yan Xia, Jane Xiang, Ning Yan, Xiaoying Zhang, Jian Zhu